Ye et al. found that the amalgamation of TGF-β shRNA and HBV double shRNA decreased blood and tissue HBV DNA, HBV RNA, and liver fibrosis indicators while enhancing the liver morphology more efficaciously than medication alone [50]. This evidence concerns the gene TGFB1 and Hepatic fibrosis.